Journal of Neuro-Oncology

, Volume 100, Issue 2, pp 165–176 | Cite as

IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines

  • Qinglin Liu
  • Gang Li
  • Ronghui Li
  • Jie shen
  • Qiaowei He
  • Lin Deng
  • Cai Zhang
  • Jian Zhang
Laboratory Investigation - Human/Animal Tissue


Interleukin-6 (IL-6) is a growth and survival factor in human glioblastoma cells and plays an important role in malignant progression. However, its role in glioblastoma invasion is still unknown. This study shows how IL-6 promotes cell invasion and migration in U251 and T98G glioblastoma cell lines. The underlying mechanism includes both protease-dependent and -independent manners. Stimulation with IL-6 increased MMP9 expression in the two cell lines but had no influence on MMP2 expression. Fascin-1 is a cell skeleton binding protein and plays a key role in cell migration and invasion. Its binding style directly influences cell morphology and tendency to become deformed. After IL-6 exposure, fascin-1 expression increased in an IL-6 dose-dependent manner. Immunofluorescence also revealed that the binding style of fascin-1 had changed after IL-6 exposure, resulting in a more invasive phenotype of the cells. Three most commonly emphasized invasion-associated signaling pathways, including JAK-STAT3, p42/44 MAPK, and PI3K/AKT, were verified to further illustrate its underlying mechanism. Only phosphorylation of STAT3 at ser 727 site paralleled the IL-6 stimulation, and JSI-124, a specific JAK-STAT3 pathway blocker, deterred the invasion and migration promotive effect of IL-6, indicating that the JAK/STAT3 pathway mediates signal transduction. Furthermore, IL-6 also acts in a paracrine fashion to promote vascular endothelial cell migration, thus facilitating tumor angiogenesis and invasion. These results suggest that IL-6 promotes glioblastoma cell invasion and angiogenesis and may be a potential anti-invasion target.


IL-6 Glioblastoma Invasion Migration Angiogenesis Fascin-1 


  1. 1.
    Ohgaki H (2009) Epidemiology of brain tumors. Methods Mol Biol 472:323–342CrossRefPubMedGoogle Scholar
  2. 2.
    Tate MC, Aghi MK (2009) Biology of angiogenesis and invasion in glioma. Neurotherapeutics 6:447–457CrossRefPubMedGoogle Scholar
  3. 3.
    Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth JA, Culig Z (2007) The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 26:2822–2832CrossRefPubMedGoogle Scholar
  4. 4.
    Badache A, Hynes NE (2001) Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res 61:383–391PubMedGoogle Scholar
  5. 5.
    Chang KT, Tsai CM, Chiou YC, Chiu CH, Jeng KS, Huang CY (2005) IL-6 induces neuroendocrine differentiation and cell proliferation in non-small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol 289:446–453CrossRefGoogle Scholar
  6. 6.
    Van Meir E, Sawamura Y, Diserens AC, Hamou MF, de Tribolet N (1990) Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res 50:6683–6688PubMedGoogle Scholar
  7. 7.
    Chang CY, Li MC, Liao SL, Huang YL, Shen CC, Pan HC (2005) Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme. J Clin Neurosci 12:930–933CrossRefPubMedGoogle Scholar
  8. 8.
    Goswami S, Gupta A, Sharma SK (1998) Interleukin-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG. J Neurochem 71:1837–1845CrossRefPubMedGoogle Scholar
  9. 9.
    Sabeh F, Shimizu-Hirota R, Weiss SJ (2009) Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J Cell Biol 185:11–19CrossRefPubMedGoogle Scholar
  10. 10.
    Luo Y, Liang F, Zhang ZY (2009) PRL1 promotes cell migration and invasion by increasing MMP2 and MMP9 expression through Src and ERK1/2 pathways. Biochemistry 48:1838–1846CrossRefPubMedGoogle Scholar
  11. 11.
    Peraud A, Mondal S, Hawkins C, Mastronardi M, Bailey K, Rutka JT (2003) Expression of fascin, an actin-bundling protein, in astrocytomas of varying grades. Brain Tumor Pathol 20:53–58CrossRefPubMedGoogle Scholar
  12. 12.
    Roma AA, Prayson RA (2005) Fascin expression in 90 patients with glioblastoma multiforme. Ann Diagn Pathol 9:307–311CrossRefPubMedGoogle Scholar
  13. 13.
    Hwang JH, Smith CA, Salhia B, Rutka JT (2008) The role of fascin in the migration and invasiveness of malignant glioma cells. Neoplasia 10:149–159CrossRefPubMedGoogle Scholar
  14. 14.
    Gunal A, Onguru O, Safali M, Beyzadeoglu M (2008) Fascin expression [corrected] in glial tumors and its prognostic significance in glioblastomas. Neuropathology 28:382–386CrossRefPubMedGoogle Scholar
  15. 15.
    Leon SP, Folkerth RD, Black PM (1996) Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77:362–372CrossRefPubMedGoogle Scholar
  16. 16.
    Kenig S, Alonso MB, Mueller MM, Lah TT (2010) Glioblastoma and endothelial cells cross-talk, mediated by SDF-1, enhances tumour invasion and endothelial proliferation by increasing expression of cathepsins B, S, and MMP-9. Cancer Lett 289:53–61CrossRefPubMedGoogle Scholar
  17. 17.
    Yao JS, Zhai W, Young WL, Yang GY (2006) Interleukin-6 triggers human cerebral endothelial cells proliferation and migration: the role for KDR and MMP-9. Biochem Biophys Res Commun 342:1396–1404CrossRefPubMedGoogle Scholar
  18. 18.
    Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, Anania FA (2007) Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 67:2497–2507CrossRefPubMedGoogle Scholar
  19. 19.
    Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, Huang S (2004) Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23:3550–3560CrossRefPubMedGoogle Scholar
  20. 20.
    Opdam FJ, Kamp M, de Bruijn R, Roos E (2004) Jak kinase activity is required for lymphoma invasion and metastasis. Oncogene 23:6647–6653CrossRefPubMedGoogle Scholar
  21. 21.
    Lee HC, Park IC, Park MJ, An S, Woo SH, Jin HO, Chung HY, Lee SJ, Gwak HS, Hong YJ, Yoo DH, Rhee CH, Hong SI (2005) Sulindac and its metabolites inhibit invasion of glioblastoma cells via down-regulation of Akt/PKB and MMP-2. J Cell Biochem 94:597–610CrossRefPubMedGoogle Scholar
  22. 22.
    Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang YJ, Lu R, Chen YX, Fang JY (2008) Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 10:287–297PubMedGoogle Scholar
  23. 23.
    Kanazawa T, Nishino H, Hasegawa M, Ohta Y, Iino Y, Ichimura K, Noda Y (2007) Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells. Eur Arch Otorhinolaryngol 264:815–821CrossRefPubMedGoogle Scholar
  24. 24.
    Walter M, Liang S, Ghosh S, Hornsby PJ, Li R (2009) Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 28:2745–2755CrossRefPubMedGoogle Scholar
  25. 25.
    Wyckoff JB, Pinner SE, Gschmeissner S, Condeelis JS, Sahai E (2006) ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr Biol 16:1515–1523CrossRefPubMedGoogle Scholar
  26. 26.
    Zhang R, Banik NL, Ray SK (2007) Combination of all-trans retinoic acid and interferon-gamma suppressed PI3K/Akt survival pathway in glioblastoma T98G cells whereas NF-kappaB survival signaling in glioblastoma U87MG cells for induction of apoptosis. Neurochem Res 32:2194–2202CrossRefPubMedGoogle Scholar
  27. 27.
    Pu P, Kang C, Zhang Z, Liu X, Jiang H (2006) Downregulation of PIK3CB by siRNA suppresses malignant glioma cell growth in vitro and in vivo. Technol Cancer Res Treat 5:271–280PubMedGoogle Scholar
  28. 28.
    Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, Thiemann M, Mueller W, Sykora J, Kuhn A, Schreglmann N, Letellier E, Zuliani C, Klussmann S, Teodorczyk M, Grone HJ, Ganten TM, Sultmann H, Tuttenberg J, von Deimling A, Regnier-Vigouroux A, Herold-Mende C, Martin-Villalba A (2008) Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13:235–248CrossRefPubMedGoogle Scholar
  29. 29.
    Fu Y, Zhang Q, Tang C, Zhang K, Zhang J, Pu P, Wang G, Wang T (2009) Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo. Cancer Biol Ther 8:1098–1105Google Scholar
  30. 30.
    Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE, Chopp M (2009) ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther 8:1141–1150CrossRefGoogle Scholar
  31. 31.
    Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S (2007) Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 121:1424–1432CrossRefPubMedGoogle Scholar
  32. 32.
    Baba Y, Iyama KI, Hirashima K, Nagai Y, Yoshida N, Hayashi N, Miyanari N, Baba H (2008) Laminin-332 promotes the invasion of oesophageal squamous cell carcinoma via PI3K activation. Br J Cancer 98:974–980CrossRefPubMedGoogle Scholar
  33. 33.
    Cheng JC, Chou CH, Kuo ML, Hsieh CY (2006) Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 25:7009–7018CrossRefPubMedGoogle Scholar
  34. 34.
    Chen PN, Hsieh YS, Chiou HL, Chu SC (2005) Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem Biol Interact 156:141–150CrossRefPubMedGoogle Scholar
  35. 35.
    Yasuda A, Sawai H, Takahashi H, Ochi N, Matsuo Y, Funahashi H, Sato M, Okada Y, Takeyama H, Manabe T (2007) Stem cell factor/c-kit receptor signaling enhances the proliferation and invasion of colorectal cancer cells through the PI3K/Akt pathway. Dig Dis Sci 52:2292–2300CrossRefPubMedGoogle Scholar
  36. 36.
    Huang C, Cao J, Huang KJ, Zhang F, Jiang T, Zhu L, Qiu ZJ (2006) Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro. Cancer Sci 97:1417–1423CrossRefPubMedGoogle Scholar
  37. 37.
    Zhao S, Venkatasubbarao K, Lazor JW, Sperry J, Jin C, Cao L, Freeman JW (2008) Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res 68:4221–4228CrossRefPubMedGoogle Scholar
  38. 38.
    Gao J, McConnell MJ, Yu B, Li J, Balko JM, Black EP, Johnson JO, Lloyd MC, Altiok S, Haura EB (2009) MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol 35:337–345PubMedGoogle Scholar
  39. 39.
    Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, Huang S (2004) Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23:3550–3560CrossRefPubMedGoogle Scholar
  40. 40.
    Fitzgerald JS, Poehlmann TG, Schleussner E, Markert UR (2008) Trophoblast invasion: the role of intracellular cytokine signalling via signal transducer and activator of transcription 3 (STAT3). Hum Reprod Update 14:335–344CrossRefPubMedGoogle Scholar
  41. 41.
    Wan XB, Long ZJ, Yan M, Xu J, Xia LP, Liu L, Zhao Y, Huang XF, Wang XR, Zhu XF, Hong MH, Liu Q (2008) Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. Carcinogenesis 29:1930–1937CrossRefPubMedGoogle Scholar
  42. 42.
    Weng CJ, Chau CF, Hsieh YS, Yang SF, Yen GC (2008) Lucidenic acid inhibits PMA-induced invasion of human hepatoma cells through inactivating MAPK/ERK signal transduction pathway and reducing binding activities of NF-kappaB and AP-1. Carcinogenesis 29:147–156CrossRefPubMedGoogle Scholar
  43. 43.
    Koochekpour S, Sartor O, Hiraiwa M, Lee TJ, Rayford W, Remmel N, Sandhoff K, Minokadeh A, Patten DY (2005) Saposin C stimulates growth and invasion, activates p42/44 and SAPK/JNK signaling pathways of MAPK and upregulates uPA/uPAR expression in prostate cancer and stromal cells. Asian J Androl 7:147–158CrossRefPubMedGoogle Scholar
  44. 44.
    Chen PN, Hsieh YS, Chiang CL, Chiou HL, Yang SF, Chu SC (2006) Silibinin inhibits invasion of oral cancer cells by suppressing the MAPK pathway. J Dent Res 85:220–225CrossRefPubMedGoogle Scholar
  45. 45.
    Huang L, Li B, Li W, Guo H, Zou F (2009) ATP-sensitive potassium channels control glioma cells proliferation by regulating ERK activity. Carcinogenesis 30:737–744CrossRefPubMedGoogle Scholar
  46. 46.
    Belsey MJ, Davies AR, Witchel HJ, Kozlowski RZ (2007) Inhibition of ERK and JNK decrease both osmosensitive taurine release and cell proliferation in glioma cells. Neurochem Res 32:1940–1949CrossRefPubMedGoogle Scholar
  47. 47.
    Jacques-Silva MC, Bernardi A, Rodnight R, Lenz G (2004) ERK, PKC and PI3K/Akt pathways mediate extracellular ATP and adenosine-induced proliferation of U138-MG human glioma cell line. Oncology 67:450–459CrossRefPubMedGoogle Scholar
  48. 48.
    Cuevas P, Diaz-Gonzalez D, Carceller F, Dujovny M (2003) Dual blockade of mitogen-activated protein kinases ERK-1 (p42) and ERK-2 (p44) and cyclic AMP response element binding protein (CREB) by neomycin inhibits glioma cell proliferation. Neurol Res 25:13–16CrossRefPubMedGoogle Scholar
  49. 49.
    Van Brocklyn J, Letterle C, Snyder P, Prior T (2002) Sphingosine-1-phosphate stimulates human glioma cell proliferation through Gi-coupled receptors: role of ERK MAP kinase and phosphatidylinositol 3-kinase beta. Cancer Lett 181:195–204CrossRefPubMedGoogle Scholar
  50. 50.
    Loeffler S, Fayard B, Weis J, Weissenberger J (2005) Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer 115:202–213CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Qinglin Liu
    • 1
  • Gang Li
    • 1
  • Ronghui Li
    • 1
  • Jie shen
    • 1
  • Qiaowei He
    • 1
  • Lin Deng
    • 1
  • Cai Zhang
    • 2
  • Jian Zhang
    • 2
  1. 1.Department of Neurosurgery, Qi Lu HospitalShandong UniversityJinanPeople’s Republic of China
  2. 2.Institute of Immunopharmacology and ImmunotherapySchool of Pharmaceutical Sciences, Shandong UniversityJinanPeople’s Republic of China

Personalised recommendations